Tag: Real World Evidence

  • EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access

    EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access

    —

    by

    in

    EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access The European Union’s Health Technology Assessment framework is transforming how pharmaceutical companies prepare clinical evidence, demonstrate therapeutic value and plan market access across Europe. As Joint Clinical Assessment (JCA) implementation progresses, manufacturers face growing pressure to align clinical development, Real-World…

  • EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?

    EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?

    —

    by

    in

    EU-HTA’s 2026 Scientific Consultation Window: Can Pharma Fix Tomorrow’s PICO Problems Before Phase III? Europe’s pharmaceutical evidence landscape is changing. Under the EU Health Technology Assessment (HTA) Regulation, generating strong clinical evidence is no longer sufficient on its own. Pharmaceutical companies must also consider whether their clinical development programmes will address the comparative evidence needs…

  • Who Gets to Define the PICO? Patient and Clinician Input in EU JCA Evidence Planning

    Who Gets to Define the PICO? Patient and Clinician Input in EU JCA Evidence Planning

    —

    by

    in

    Who Gets to Define the PICO? Why Patient and Clinician Input Matters for EU JCA Evidence Planning A treatment may perform well in a clinical trial. But does the evidence answer the questions that matter to patients, clinicians and HTA assessors across Europe? That question is becoming harder to leave until submission. On 14 September…

  • EU JCA Evidence Requirements: Lessons for Pharma in 2026

    EU JCA Evidence Requirements: Lessons for Pharma in 2026

    —

    by

    in

    EU JCA Is Now Operational: What the First Assessments Reveal About Evidence, RWE and Market Access The European Union’s Joint Clinical Assessment framework has moved decisively from policy into practice. Since the EU Health Technology Assessment Regulation became applicable in January 2025, pharmaceutical and biotechnology companies have been preparing for new timelines, evidence requirements and…

  • EMA and EU-HTA Alignment: One Evidence Strategy for Regulatory Approval and JCA

    EMA and EU-HTA Alignment: One Evidence Strategy for Regulatory Approval and JCA

    —

    by

    in

    EMA and EU-HTA Alignment Building One Evidence Strategy for Regulatory Approval and Joint Clinical Assessment Europe’s evidence environment has entered a new phase. A medicine can now move through the European Medicines Agency’s regulatory assessment while, in parallel, entering the EU-level Joint Clinical Assessment process. These procedures remain legally and methodologically distinct, but manufacturers must…

  • JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams

    JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams

    —

    by

    in

    JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams The European Union Health Technology Assessment Regulation has created a common framework for assessing the relative clinical effectiveness and safety of eligible health technologies. However, the introduction of Joint Clinical Assessment does not establish a single European pricing, reimbursement or market-access…

  • EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential

    EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential

    —

    by

    in

    EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.…

  • Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission

    Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission

    —

    by

    in

    Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…

  • From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma's Competitive Advantage Under EU HTA

    From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA

    —

    by

    in

    From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…

  • DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE

    DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE

    —

    by

    in

    Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…